The Future of Miniaturised Organs in Drug Development and Testing by Chisholm, Timothy
The Future of Miniaturised Organs in Drug
Development and Testing





Drug development is time consuming and expensive, partly due to the difficulty of
determining the safety and effectiveness of drugs in humans. To improve this process,
there is a demand for models appropriate for studying the biological effects of drugs
early in their development. This article considers miniaturised organ technology to
evaluate the safety and efficacy of medicines and reduce our dependence on animal
testing. Testing drugs on miniaturised organs could also help account for systematic
biases in clinical trial populations. However, ethical concerns exist including patient
consent and the anonymisation of tissue donations. This article considers these key
concerns and provides policy recommendations for the ethical and responsible use of
miniaturised organ technology.
Science ⇒ Policy
Miniaturised organs grown from human tissue are showing promise as tools to test
drug safety and efficacy. This technology could reduce the need for animal testing
and help account for systemic biases in clinical trials. Policies are needed to ensure
this technology is adopted responsibly, and to address ethical concerns around patient
consent and donor anonymisation.
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Aim and Objectives
The aim of this article is to outline applications
of testing drugs on miniaturised organs and to
discuss the implications this technology has for
policy. The benefits of this technology in drug
development and clinical trials will be evaluated,
followed by a discussion of related ethical con-
cerns. Policy recommendations will then be made
to address these concerns and promote a positive
impact of this technology.
Scientific Background
Drug development is a lengthy and expensive
process (Figure 1) [1, 2]. Candidate drugs are
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discovered and developed, then undergo animal
testing in pre-clinical trials to investigate safety
and the effects of the drug on a living organism.
If these results are promising, the safety and effi-
cacy of the drug is tested with human subjects
in clinical trials before regulatory approval.
Advances in chemistry and biology have improved
the design and synthesis of medicines. However,
testing the safety and efficacy of new drugs re-
mains challenging. Testing drugs in animals has
ethical considerations and it imprecisely models
how the drug will affect humans [1, 2]. Addition-
ally, drugs can have different efficacies and safety
profiles in different people [3–11].
These issues may be addressed with the help of
organoids and organs-on-chips, which are simpli-
fied, miniaturised humans organs (Figure 2) [12].
To grow organoids, adult human cells are repro-
grammed into a stem cell, a type of progenitor cell
that can develop into different cell types (Figure
2a). Stem cells are embedded in a gel where they
divide and specialise into specific cell types, pro-
ducing an organoid [13, 14]. Organs-on-chips are
grown with a different approach. In the simplest
form, a narrow tube containing a single cell type
is used [15–17]. More complex systems can be
fabricated with multiple types of cells separated
by porous membranes (Figure 2b). Fluid can be
pumped through the tubing for several purposes,
such as mimicking blood flow.
One application of miniaturised organs is to test
the safety and efficacy of drugs [15–20]. A lim-
itation of animal models for drug testing is the
difference between human and test animal biol-
ogy, especially liver and kidney physiology [21–
25]. Drugs are processed by the liver, producing
by-products which are excreted by the kidneys
into urine. Differences in human and test animal
physiology mean that drugs may be processed and
excreted differently [23–25]. For example, toxic
by-products may be produced and accumulate in
humans but not some animals [22–27].
As miniaturised organs are grown from human tis-
sue, they can more closely mirror parts of human
physiology than test animals [28–36]. Testing
medicines on miniaturised organs could there-
fore provide safety and efficacy data that ani-
mal models cannot [28–32, 35–41]. However, an-
imal models remain the only method to study
drugs in living organisms with fully grown, in-
terconnected organ systems before human trials.
Both testing methods therefore have their ad-
vantages. Miniaturised organ testing could be
used to screen drugs prior to animal testing and,
as the technology advances, could further com-
plement and replace aspects of animal testing
[13–16, 19, 28, 35, 42]. The ideal outcome, which
policy should support, is more efficient drug de-
velopment that delivers safer and more effective
drug candidates with reduced animal use.
Policy Implications
Policies and regulations that outline how testing
drugs on miniaturised organs can be considered
in the drug development process are required.
Miniaturised organ testing may identify safety
or efficacy concerns that would remain unidenti-
fied until animal or human trials [14–16, 42, 43].
This approach would address a demand for the
reduction of animal testing by medical and regula-
tory agencies, including the European Medicines
Agency (EMA) [29, 30, 44–48]. However, uncer-
tainty regarding how these technologies will be
considered by regulators is hampering the adop-
tion of miniaturised organ testing. The EMA
states: “. . . the uptake of these newer models
[miniaturised organ testing] in marketing autho-
risation submissions has not been high ... One
reason for hesitancy may be concerns . . . that use
of such New Approach Methodologies (NAMs)
will not be acceptable to regulators and will thus
stall approvals . . . Encouragement of these tech-
niques is therefore needed” [46].
In addition to this apparent lack of clear regula-
tory guidelines, the EMA suggests that a lack of
knowledge of such models and high implementa-
tion costs also play a role. If regulators outline
how they would consider miniaturised organ test-
ing, this could improve the confidence of pharma-
ceutical companies in this technology, increasing
uptake.
Miniaturised organ testing can also help account
for biases in clinical trials, which generally over-
represent men of European descent [3, 5]. While
recent trials exhibit an improved gender bal-
ance, many groups remain underrepresented. The
safety and efficacy of medicines are therefore not
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Figure 1: Drug Discovery and Development Pipeline. Overview of a traditional drug discovery
and development pipeline with approximate values for the time taken and the number of chemicals at
each stage. Figure adapted from Matthews et al. and Paul et al. [1, 2].
Figure 2: The Construction of Organoids and Organ-on-Chips. a) Organoids are grown by
reprogramming an adult cell into a stem cell, which can specialise into different cell types under specific
conditions. Stem cells are embedded into a gel that acts as a scaffold in which the stem cells divide,
specialise, and grow into an organoid. b) An organ-on-a-chip containing two cell types. Two halves of
a channel are prepared; one half containing a layer of one type of cell, and the other half containing
another cell type. These halves are then connected with a porous membrane and the channel sealed.
The resulting narrow tube has two cell types separated by a membrane, and an empty channel through
which fluid can be passed.
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assessed for all demographics equally. As a result,
medical treatments may have different efficacies
and safety profiles in women and ethnic minori-
ties [3–11]. Using miniaturised organs derived
from these underrepresented demographics could
improve medical outcomes and help amend the
existing biases in clinical trial populations. This
approach is particularly relevant for completed
clinical trials, whereas future clinical trials still
require representative populations for the best
medical outcomes.
Miniaturised organs also raise ethical challenges,
particularly regarding the anonymisation of dona-
tions and the level of consent provided by donors
[49–54]. Complete anonymisation of biological
samples usually cannot be guaranteed, and re-
identification may be preferred if research reveals
health concerns the donor may face [49, 50, 54–57].
Donors should also explicitly consent to tissue col-
lection and the specific uses of their tissue [51, 58].
Additionally, donors cannot give informed con-
sent for all future uses of donated tissue when
new applications are constantly discovered. An
approach of ongoing consent may therefore be
suitable where donors are contacted to consent
for new uses of their tissues [49, 58, 59].
The European General Data Protection Regula-
tion (GDPR) was updated in 2018 with implica-
tions for research involving stem cells, including
miniaturised organ research [57]. However, bio-
logical samples face unique challenges such as the
inability to definitively anonymise samples. Sim-
ilar ethical and regulatory issues were faced by
stem cell technology and many remain unresolved,
despite regulations like the GDPR. Regulations
which are specific for biological applications are
therefore needed [57–62].
Policy Recommendations
The implementation of miniaturised organ tech-
nology faces several challenges as outlined above.
Some brief recommendations for policy develop-
ment in these areas are described:
Miniaturised Organ Testing in
Drug Development
Regulators should outline what they consider to
be important applications of miniaturised organ
testing in drug development, and how these ap-
plications could be implemented alongside ani-
mal testing. For example, drug testing could be
performed on liver organoids to identify toxic
by-products prior to animal testing. Regulators
should provide a roadmap detailing how minia-
turised organ testing might be considered in the
drug approval process as the technology develops.
Miniaturised Organ Testing for
Historical Clinical Trials
Many previous clinical trial populations under-
represent women and ethnic minorities [3–11].
Pharmaceutical companies should be incentivised
to test medicines on miniaturised organs derived
from these underrepresented groups. One solu-
tion is to implement policies that extend patent
protection of a therapeutic in exchange for per-
forming this testing.
Consent and Anonymisation in
Miniaturised Organs Technology
Policies addressing the ethical concerns arising
from miniaturised organ technology should be
developed. Anonymisation and consent are par-
ticularly important [49–51]. Donations should
require informed consent and for the donor to be
aware of what degree of anonymisation is possible
[54]. The donor should also agree to conditions
in which they will be re-identified or contacted if
new uses of their donated tissue are desired, or
research using their tissue suggests a particular
health risk. In the latter case the decision to con-
tact the donor should be rapid, aligned with the
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donor’s consent, and should involve the donor’s
primary healthcare provider if appropriate.
Conclusion
Miniaturised organ testing has the potential to
make drug development more efficient and ethi-
cal, and to partially address historical biases in
clinical trials. However, proactive policies and
regulations are needed to promote the beneficial
uptake of this technology and to limit ethical
risks. Clear regulatory guidelines are required
to give businesses confidence that miniaturised
organ testing will be supported in drug devel-
opment. Pharmaceutical companies should also
be incentivised to perform miniaturised organ
testing for drugs where clinical trials have been
completed but involved unrepresentative popu-
lations. Yet, these benefits of using organoids
are marred by ethical challenges. Proactively ad-
dressing these issues will best allow the benefits
of this technology to be realised.
© 2021 The Author(s). Published by the Cambridge
University Science & Policy Exchange under the
terms of the Creative Commons Attribution License
http://creativecommons.org/licenses/by/4.0/,
which permits unrestricted use, provided the original
author and source are credited.
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